Answers are grounded in this paper and cite their sources.
Observational study examines BMI responses in Saudi Arabia, highlighting the importance of obesity class.
BACKGROUND: Obesity is highly prevalent in Saudi Arabia and is a primary therapeutic target for SGLT2 inhibitors and GLP-1 receptor agonists. Whether BMI response to dapagliflozin ± semaglutide varies across WHO BMI classes remains incompletely characterized. OBJECTIVE: To examine absolute and proportional BMI changes across WHO BMI classes in a real-world Saudi cohort, using normal weight as the reference group. METHODS: A retrospective observational cohort of 328 patients initiated on dapagliflozin ± once-weekly semaglutide at King Abdulaziz Hospital, MNGHA, Al-Ahsa (follow-up 90-365 days). The primary outcome was absolute ΔBMI; secondary outcomes included proportional BMI change and ≥5% reduction. Multivariable sensitivity analysis adjusted for age, baseline BMI, treatment group, and sex. Dapagliflozin 10 mg once daily was the only available formulation; individual semaglutide dose data were unavailable. RESULTS: Normal (n = 23), overweight (n = 57), obesity I (n = 87), obesity II (n = 89), obesity III (n = 72). Absolute ΔBMI differed significantly across classes (Kruskal-Wallis, p = 0.005), with the greatest reduction in Obesity III (-1.05 vs. -0.09 kg/m² in Normal; Bonferroni p_adj = 0.017). Proportional change was uniform (p = 0.182), indicating the absolute gradient reflects higher baseline BMI. Baseline BMI was the dominant predictor (β = -0.38, p < 0.001); Obesity III retained independent association (β = -0.59, p = 0.021). CONCLUSIONS: Absolute BMI reduction was greatest in Obesity III, but proportional response was uniform across classes, reflecting baseline BMI rather than class-specific pharmacological advantage. Semaglutide add-on showed a directional trend toward greater benefit in obesity I. These exploratory findings support obesity-class-informed monitoring and provide a basis for prospective studies.
No takes yet. Share an insight, caveat, or question.
AlTaweel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: